Actifol® 1 mg Overview
Fertility and having children have always been considered as blessings from God in the traditional societies and have cultural importance(1).
Infertility is known to cause an impact on the mental health of the infertile couple, causing anxiety, depression, social isolation and sexual dysfunction. The high level of psychosocial distress has a direct impact on the couple’s marital and sexual relations (2).
On the other hand, women with risk of miscarriage express emotional and unstable behavior. The predominant emotions of women with high risk of miscarriage are fear, anxiety and prenatal emotional connection with a child deficiency, depression and loneliness (3).
What remains evident is that the wellbeing of the couple marital status and satisfaction is directly related to having children.
(1) Int J Reprod BioMed, December 2016
(2) J Hum Reprod Sci. 2011
(3) Res Rep Gynaecol Obstet. 2017
Product Information/1 tablet:
L-5 Methyltetrahydrofolic Acid (Quatrefolic®): 1 mg
Boosts the Sense of Optimism for Successful Pregnancy
is a registered TRADEMARK of Omicron Pharmaceuticals Int.
Folate & Infertility
Studies among couples undergoing infertility treatment in Europe suggest that folate may improve reproductive success.
Higher supplemental folate intake was associated with higher fertilization rates and lower cycle failure rates before embryo transfer and was related to a higher probability of live birth among women undergoing Assisted Reproductive Technology (ART).
Obstet Gynecol. October 2014
Prescribe Actifol® 1 mg to Secure a Positive Pregnancy Outcome
is a registered TRADEMARK of Omicron Pharmaceuticals Int.
Folate & Recurrent Miscarriages
Studies showed that women have 45 to 70 % higher risk of recurrent pregnancy loss due to improper metabolism of folic acid as a consequence of MTHFR mutation in comparison to those who do not have the mutation (1).
There is no longer doubt as to a negative correlation between the MTHRF gene mutation and recurrent miscarriages where they initially cause significant chromosomal disorders during the early preimplantation stages then recurrent pregnancy loss in later stages (2).
The only solution is to use Fully Active Folate (FAF) rather than folic acid avoiding any essential activation step by MTHFR.
(1) Reproductive Sciences 2015
(2) Gynécologie Obstétrique Fertilité & Sénologie October 2019
Prescribe Actifol® 1 mg to Prevent Recurrent Miscarriages
is a registered TRADEMARK of Omicron Pharmaceuticals Int.
Why Actifol® 1 mg
⇒ 30 couples with a long history (at least 4 years) of recurrent miscarriages or infertility previously treated unsuccessfully with high doses of folic acid ( 5 mg/day)
⇒ 800 mcg/day of Fully Active Folate (FAF) was used for 4 months
Results:
⇒ 14 spontaneous pregnancies
⇒ 13 pregnancies after Assisted Reproductive Technology (ART)
J Assist Reprod Genet 35, 1431-1435 (2018)
Actifol® 1 mg avoids potential adverse effects of the UMFA syndrome and secures positive pregnancy outcome
The Only Fully Active Folate to Secure Successful Conception and Recurrent Miscarriages Prevention
86.7 % successful ongoing pregnancy rate
is a registered TRADEMARK of Omicron Pharmaceuticals Int.